ReviewFrontiers in aging neuroscience2020
The Neuroimmunology of Guillain-Barré Syndrome and the Potential Role of an Aging Immune System.
Review in Frontiers in aging neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- A systematic review of CRISPR applications in demyelinating peripheral nervous system disorders.Regenerative medicine · 2025Pooled it
- Association between Guillain-Barré syndrome and SARS-CoV-2 virus infection, including the impact of COVID-19 vaccination in the context of the development and general clinical characteristics of the disease.Journal of neurovirology · 2025Pooled it
- The neutrophil-to-lymphocyte ratio as a prognostic biomarker in Guillain-Barre syndrome: a systematic review with meta-analysis.Frontiers in neurology · 2023Pooled it
- Role of the Neutrophil to Lymphocyte Ratio in Guillain Barré Syndrome: A Systematic Review and Meta-Analysis.Mediators of inflammation · 2022Pooled it
- Neuro-immune interactions in tumors, immune-related disorders, and infections.Signal transduction and targeted therapy · 2026Review
- Dynamic Changes and Future Trend Forecasts in the Global Burden of Guillain-Barré Syndrome: Analysis of 204 Countries and Regions From 1990 to 2021, Including the Impact of the COVID-19 Pandemic.Immunity, inflammation and disease · 2026Observational
- Disproportionality Analysis and Timing of Drug-Associated Guillain-Barré Syndrome Onset Based on the Japanese Adverse Drug Event Report Database.Pharmaceuticals (Basel, Switzerland) · 2026Article
- C-Reactive Protein and Neurological Autoimmune Diseases: Bridging the Diagnostic and Pathogenic Gap.International journal of molecular sciences · 2026Review
- Guillain-Barré Syndrome in Older People-A Case Report and Literature Review.Diseases (Basel, Switzerland) · 2025Review
- COVID-19 vaccines and neurological disorders: A narrative review of immune responses and adverse reactions.AIMS neuroscience · 2025Review
- Evolving understanding of Guillain-Barré syndrome pathophysiology and the central role of the classical complement pathway in axonal injury.Frontiers in neurology · 2025Article
- Rapid Paralysis and Hidden Malignancy: Acute Motor Axonal Neuropathy Revealing Pleomorphic Liposarcoma.European journal of case reports in internal medicine · 2025Article
- The Role of Phytochemicals in Managing Neuropathic Pain: How Much Progress Have We Made?Nutrients · 2024Review
- A retrospective analysis of the clinical profile and factors associated with mortality and poor hospital outcomes in adult Guillain-Barre syndrome patients.Scientific reports · 2024Article
- Article
- Guillain-Barre syndrome and link with COVID-19 infection and vaccination: a review of literature.Frontiers in neurology · 2024Review
- Incidence of Guillain-Barré syndrome in the world between 1985 and 2020: A systematic review.Global epidemiology · 2023Review
- The characteristics of Guillain-Barre syndrome in children in pre-COVID-19 and during the COVID-19 pandemic: A cross-sectional study.Health science reports · 2023Article
- Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications.International journal of molecular sciences · 2023Review
- COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.Immunity, inflammation and disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS) is a paralyzing autoimmune condition affecting the peripheral nervous system (PNS). Within GBS there are several variants affecting different aspects of the peripheral nerve. In general, there appears to be a role for T cells, macrophages, B cells, and complement in initiating and perpetuating attacks on gangliosides of Schwann cells and axons. Of note, GBS has an increased prevalence and severity with increasing age. In addition, there are alterations in immune cell functioning that may play a role in differences in GBS with age alongside general age-related declines in reparative processes (e.g., delayed de-differentiation of Schwann cells and decline in phagocytic ability of macrophages). The present review will explore the immune response in GBS as well as in animal models of several variants of the disorder. In addition, the potential involvement of an aging immune system in contributing to the increased prevalence and severity of GBS with age will be theorized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.